Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 510 participants.
Also called NCT03568890
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 510 participants
- Registry
-
NCT03568890
-
- Other papers using this trial's data
- Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03568890. Randomized; no masking; primary purpose prevention. Start 2018-09-01 (actual); primary completion 2025-08-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
- Acronym
- ANDES
- Condition
- Left Atrial Appendage Closure
- Condition
- Thrombosis
- Condition
- Stroke
- Condition
- TIA (transient ischemic attack)
- Condition
- Bleeding
- Intervention (Drug)
- Rivaroxaban, dabigatran, apixaban, or edoxaban
- Intervention (Drug)
- Clopidogrel -75 mg/day
- Intervention (Drug)
- Low dose aspirin -80 to 125 mg/day-
- Lead sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Record details
- Record id
cardio:ct-nct03568890- Content hash
0f598330ffc91c33f3c6705087853411bcdcb57422df722677e5ab2115eee50f